Novo Nordisk: The Sell-Off Is Getting Absolutely Ridiculous

Novo Nordisk’s share sell‑off reflects investor concern after a November agreement to cut list prices for Ozempic/Wegovy (and some insulins) effective 2026, reduced self‑pay pricing ($199–$349/month), and lowered 2025 guidance amid intensifying competition from Eli Lilly, even as the company anticipates Medicare Part D coverage expansion and negligible single‑digit worldwide sales impact in 2026 that could broaden access and provide regulatory stability. The note warns policy risk, competitive pressure on pricing and product mix, and operational constraints (supply/refill volatility) remain material. Using conservative valuation assumptions (2025 revenue $49.6bn, 45% EBIT margin, 76% FCF conversion, 9.5% WACC, 3.5% terminal growth) the analysis finds the stock is at least fairly valued and potentially 35% undervalued if obesity sales stall and up to ~85% undervalued if obesity market growth plays out, leading to a conviction buy despite the acknowledged risks.

Analysis

Novo Nordisk's recent share weakness is driven primarily by a November agreement to lower list prices for Ozempic and Wegovy (and reductions for insulins like Fiasp and Tresiba) effective in 2026, a marked cut in self-pay pricing to $199–$349/month, and a lowered 2025 revenue guide that the market penalized. The company expects Medicare Part D to extend obesity drug coverage and anticipates a negligible single-digit impact on worldwide sales in 2026, with private insurers likely to follow Medicare's lead, creating greater access but compressing list pricing.

A conservative valuation using 2025 revenue held at the TTM $49.6bn, a 45% EBIT margin, 76% FCF conversion, a 9.5% WACC and 3.5% terminal growth produces scenario outcomes ranging from fair value (no growth) to a $284bn implied market cap (35% undervalued if obesity stalls) and up to ~85% undervaluation if obesity market growth (~20% assumed) materializes; market sentiment is bullish (sentiment_score 0.68, NVO 0.8) but market_impact_score is modest at 0.25.

Key risks that could reverse the positive valuation skew are political/regulatory changes that widen mandatory pricing cuts, intensified competition from Eli Lilly and emerging oral GLP-1s, and operational constraints including supply and refill volatility; a speculative upside catalyst is an upcoming Alzheimer trial readout mentioned by management. The article's author rates NVO a Strong Buy and reports doubling personal exposure, but investors should balance the indicated upside against the identified policy and competitive execution risks.

Key Decisions for Investors

• Consider accumulating or adding to NVO on meaningful weakness given conservative DCF scenarios showing 35%–85% upside potential, but scale position size to reflect regulatory and competitive uncertainty
• Monitor policy milestones closely—use the 2026 Medicare Part D implementation and any subsequent mandatory pricing announcements as decision points to trim or hedge exposure if broader price controls appear
• Track operational and competitive indicators each quarter: refill rates, production scaling, Eli Lilly market-share trends, and actual revenue vs. the ~11% near-term growth management still cites, and reduce conviction if trends worsen
• If downside protection is desired, implement size-constrained hedges (protective puts or collars) rather than outright avoidance, and treat the Alzheimer trial readout as a speculative catalyst rather than a basis for core position sizing